Sorry, you need to enable JavaScript to visit this website.

Studies in Additional Populations

Pregnant Women

In February 2021, Pfizer and BioNTech dosed the first participant in a global Phase 2/3 study to further evaluate the safety, tolerability, and immunogenicity of the Pfizer-BioNTech COVID-19 vaccine in preventing COVID-19 in healthy pregnant women 18 years of age and older.

 

Children Under 12

In March 2021, Pfizer and BioNTech dosed the first healthy children in a global Phase 1/2/3 continuous study to further evaluate the safety, tolerability, and immunogenicity of the Pfizer-BioNTech COVID-19 vaccine in children 11 years to 6 month old.